AHCY: A Drug Target / Disease Biomarker (G191)

Target Name: AHCY

NCBI ID: G191

AHCY

AHCY: A Drug Target / Disease Biomarker

AHCYis a drug target and a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Its unique structure and function have made it an attractive target for drug development.

AHCY is a small molecule that is expressed in various tissues and has been shown to play a role in various physiological processes. One of its most notable functions is its role in the regulation of cell death, which is essential for the development and maintenance of tissues and organs.

AHCY has been shown to be involved in a variety of cellular processes, including the regulation of cell apoptosis, cell cycle progression, and protein synthesis. It has also been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway.

AHCY has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. For example, studies have shown that AHCY levels are elevated in various tissues of cancer patients and that inhibition of AHCY has been shown to protect against the development of cancer.

AHCY has also been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease. Studies have shown that AHCY levels are elevated in the brains of individuals with these disorders and that inhibition of AHCY has been shown to protect against the progression of neurodegenerative disorders.

AHCY has also been shown to be involved in the development of cardiovascular diseases, such as heart failure and hypertension. Studies have shown that AHCY levels are elevated in the hearts of individuals with these conditions and that inhibition of AHCY has been shown to protect against the development of cardiovascular disease.

In addition to its potential therapeutic uses, AHCY has also been shown to be a potential biomarker for various diseases. Studies have shown that AHCY levels are elevated in the brains, hearts, and other tissues of individuals with various diseases, including cancer, neurodegenerative disorders, and cardiovascular disease. This suggests that AHCY may be a useful biomarker for these diseases and that its levels may be a useful indicator of disease progression.

Overall, AHCY is a drug target and a potential biomarker for a variety of diseases. Its unique structure and function make it an attractive target for drug development and its potential as a biomarker makes it an important area of research. Further studies are needed to fully understand the role of AHCY in these diseases and to develop safe and effective treatments.

Protein Name: Adenosylhomocysteinase

Functions: Catalyzes the hydrolysis of S-adenosyl-L-homocysteine to form adenosine and homocysteine (PubMed:10933798). Binds copper ions (By similarity)

The "AHCY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AHCY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets